Dr Reddys Laboratories Ltd News

Dr Reddy's enters hormone replacement therapy segment with $32 mn buy

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

Stocks to Watch today, Feb 19: Dr Reddy's Labs, HUL, Cochin Shipyard, DLF

Stocks to Watch today, February 19, 2025: Dr Reddy's Labs, Hindustan Unilever, NCC, DLF, and Jindal Saw are some of the key stocks to watch today

Dr Reddy's: 5 technical reasons why Choice Broking is bullish on this stock

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

US market remained a drag for Indian pharma in Q3 amid pricing pressure

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

India-EU FTA: Brokerages decode impact for markets, sectors, companies

In fiscal 2024-25 (FY25), India, according to HSBC, exported $76 billion worth of goods to the EU and bought $61 billion worth of goods from the EU

Dr Reddy's Laboratories gains 5% on posting Q3 results; brokerages divided

In Q3, Dr Reddy's Laboratories reported a 14 per cent year-on-year (Y-o-Y) decline in consolidated net profit to ₹1,210 crore, as compared to ₹1,413 crore a year ago

Stocks to watch, Jan 22: Eternal, Dr Reddys, IndiGo, DLF, HPCL, PNB Housing

Stocks to watch on Thursday, January 22, 2026: KEI Industries, Bajaj Consumer Care, PNB Housing Finance and Jindal Stainless are among other key stocks to track today

Dr Reddy's Q3 PAT down 14% Y-o-Y on low Lenalidomide sales in US

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Q3 results today: Dr Reddy's Lab, Eternal, Hindustan Petroleum on Jan 21

Q3FY26 company results: Firms including Bank of India, Jindal Stainless, PNB Housing Finance, and Tata Communications are also to release their October-December earnings reports today

Stocks to watch, Jan 21: Dr Reddys, Eternal, Persistent Sys, United Spirits

Stocks to watch today, Wednesday, January 21, 2026: Cyient DLM, Shoppers Stop, HDFC Bank, Tata Steel, and Vikram Solar are among other key stocks to track today.

Stocks to Watch today, Jan 16: RIL, Infosys, ICICI Pru AMC, Jio Financial

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Stocks to Watch today, Jan 7: Titan, Biocon, Godrej Con, Lodha, YES Bank

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

Dr Reddy's Laboratories launches hepatitis E vaccine Hevaxin in India

The company said Hevaxin is the only hepatitis E vaccine approved by the Drug Controller General of India (DCGI) and is indicated for active immunisation against HEV infection

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Stocks to Watch today, Dec 15: Swiggy, BEL, Tata Elxsi, Aurobindo Pharma

Stocks to watch today, December 15, 2025: From Tata Elxsi to Aurobindo Pharma, here is a list of stocks to keep in focus

Larger HC Bench clears way for export of semaglutide generics by Dr Reddy's

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Dr Reddy's signs licensing pact to sell Australian Immutep's cancer drug

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market